Bone marrow mesenchymal stem cells from multiple myeloma patients aberrantly affect chemotactic function of myeloma cell lines

doi:10.3969/j.issn.2095-4344.2015.50.001

Abstract

Abstract:

BACKGROUND: Although bone marrow mesenchymal stem cells from multiple myeloma patients present a variety of abnormalities, it is unclear how these abnormal mesenchymal stem cells influence the chemotactic function of myeloma cell lines.
OBJECTIVE: To investigate the in vitro effects of bone marrow mesenchymal stem cells from normal donors versus multiple myeloma patients on the chemotactic capacity of myeloma cell lines.
METHODS: In vitro cultured bone marrow mesenchymal stem cells derived from either normal donors (N-MSCs group) or newly-diagnosed multiple myeloma patients (MN-MSCs group) were directly co-cultured with U266 cells, in the presence or absence of bortezomib; and then harvested U266 cells were assayed for Transwell migration
and mRAN expression of chemotaxis-related genes. U266 Transwell migration to conditioned medium derived from either N-MSCs or MN-MSCs was also tested.
RESULTS AND CONCLUSION: After co-cultured with N-MSCs or MN-MSCs, U266 cells harvested from MN-MSCs group showed increased spontaneous Transwell migration and up-regulated CCR1 mRNA level than those from N-MSCs group (P < 0.05), whatever bortezomib was present or not. However, there was no evident difference between U266 cell Transwell migration to conditioned medium derived from either MM-MSCs group or N-MSCs group. Our study implies that there may be some intrinsic aberrance in bone marrow mesenchymal stem cells derived from multiple myeloma patients, which can modulate the chemotactic migration of myeloma cell lines when they directly interact with each other.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

CLC Number:

R394.2

Fei Xiao-ming, Li Jun-xia, Tang Yu, Lei Fang, Lu Hua. Bone marrow mesenchymal stem cells from multiple myeloma patients aberrantly affect chemotactic function of myeloma cell lines[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(50): 8037-8042.

Figures/Tables 3

References

[1] Raab MS, Podar K, Breitkreutz I, et al. Multiple myeloma. Lancet. 2009;374(9686):324-339.

[2] Zingone A, Kuehl WM. Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol. 2011;48(1):4-12.

[3] Colombo M, Mirandola L, Platonova N, et al. Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes. Leukemia. 2013;27(5):1009-1018.

[4] Manier S, Sacco A, Leleu X, et al. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496.

[5] Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341-4351.

[6] Jurczyszyn A, Czepiel J, Gdula-Argasińska J, et al. The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment. J Cancer. 2015;6(2):160-168.

[7] García-Gómez I, Elvira G, Zapata AG, et al. Mesenchymal stem cells: biological properties and clinical applications. Expert Opin Biol Ther. 2010;10(10):1453-1468.

[8] Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143-147.

[9] Wang X, Zhang Z, Yao C. Angiogenic activity of mesenchymal stem cells in multiple myeloma. Cancer Invest. 2011;29(1): 37-41.

[10] Todoerti K, Lisignoli G, Storti P, et al. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. Exp Hematol. 2010;38(2):141-153.

[11] Li B, Fu J, Chen P, et al. Impairment in immunomodulatory function of mesenchymal stem cells from multiple myeloma patients. Arch Med Res. 2010;41(8):623-633.

[12] 李俊霞,李皎,王欢,等.骨髓瘤细胞可诱导骨髓间充质干细胞的基因表达谱发生暂时和(或)长期性改变[J].南京医科大学学报:自然科学版,2013, 33(1): 86-92.

[13] Xu X, Yang J, Tang Y, et al. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib. Int J Clin Exp Pathol. 2014;7(10):6705-6715.

[14] Holt RU, Fagerli UM, Baykov V, et al. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica. 2008;93(4):619-622.

[15] Hu Y, Sun CY, Wang HF, et al. Brain-derived neurotrophic factor promotes growth and migration of multiple myeloma cells. Cancer Genet Cytogenet. 2006;169(1):12-20.

[16] Zipori D. The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. Cancer Microenviron. 2010;3(1):15-28.

[17] Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011;94(4):334-343.

[18] Hecht M, Heider U, Kaiser M, et al. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol. 2007;138(4):446-458.

[19] Menu E, Asosingh K, Indraccolo S, et al. The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model. Haematologica. 2006; 91(5):605-612.

[20] Beider K, Begin M, Abraham M, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011;39(3):282-292.

[21] Giuliani N, Bonomini S, Romagnani P, et al. CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica. 2006;91(11):1489-1497.

[22] Trentin L, Miorin M, Facco M, et al. Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. Br J Haematol. 2007;138(5):594-602.

[23] Dairaghi DJ, Oyajobi BO, Gupta A, et al. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012;120(7): 1449-1457.

[24] Vande Broek I, Leleu X, Schots R, et al. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematologica. 2006;91(2): 200-206.

[25] Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood. 2003;101(7):2775-2783.

[26] Garcia-Gomez A, De Las Rivas J, Ocio EM, et al. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget. 2014;5(18):8284-8305.

[27] Abdi J, Mutis T, Garssen J, et al. Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib- induced apoptosis. PLoS One. 2014;9(5):e96608.

[28] Murray ME, Gavile CM, Nair JR, et al. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood. 2014;123(24):3770-3779.

[29] Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Semin Hematol. 2012;49(3):228-242.

[30] Hao M, Zhang L, An G, et al. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011;52(9):1787-1794.

[31] Markovina S, Callander NS, O'Connor SL, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer. 2010;9:176.

[32] Chang J, Liu F, Lee M, et al. NF-κB inhibits osteogenic differentiation of mesenchymal stem cells by promoting β-catenin degradation. Proc Natl Acad Sci U S A. 2013; 110(23):9469-9474.